616 related articles for article (PubMed ID: 28880983)
21. The trials and tribulations of CAR-T cell development for cancer and AIDS.
Hege K
Nat Med; 2019 Aug; 25(8):1183. PubMed ID: 31388173
[No Abstract] [Full Text] [Related]
22. CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy.
Samadani AA; Keymoradzdeh A; Shams S; Soleymanpour A; Rashidy-Pour A; Hashemian H; Vahidi S; Norollahi SE
Int Immunopharmacol; 2021 Jan; 90():107201. PubMed ID: 33249047
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
24. Next Steps in the CAR Journey of a Thousand Miles.
Brenner MK
Mol Ther; 2017 Oct; 25(10):2226-2227. PubMed ID: 28939089
[No Abstract] [Full Text] [Related]
25. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.
Jhaveri KD; Rosner MH
Clin J Am Soc Nephrol; 2018 May; 13(5):796-798. PubMed ID: 29523675
[No Abstract] [Full Text] [Related]
27. Chimeric Antigen Receptor T-Cell Therapy.
Ogba N; Arwood NM; Bartlett NL; Bloom M; Brown P; Brown C; Budde EL; Carlson R; Farnia S; Fry TJ; Garber M; Gardner RA; Gurschick L; Kropf P; Reitan JJ; Sauter C; Shah B; Shpall EJ; Rosen ST
J Natl Compr Canc Netw; 2018 Sep; 16(9):1092-1106. PubMed ID: 30181421
[TBL] [Abstract][Full Text] [Related]
28. First Chimeric Antigen Receptor T-Cell Therapy Approved.
Brower V
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29106609
[No Abstract] [Full Text] [Related]
29. [Perspectives for the evolution and use of CAR-T cells].
Genebrier S; Tarte K
Bull Cancer; 2021 Oct; 108(10S):S18-S27. PubMed ID: 34920801
[TBL] [Abstract][Full Text] [Related]
30. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
32. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
Alcantara M; Tesio M; June CH; Houot R
Leukemia; 2018 Nov; 32(11):2307-2315. PubMed ID: 30315238
[TBL] [Abstract][Full Text] [Related]
33. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
Hardaway JC; Prince E; Arepally A; Katz SC
J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
[No Abstract] [Full Text] [Related]
34. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
35. CAR T cells - what have we learnt?
Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589
[No Abstract] [Full Text] [Related]
36. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J
Front Immunol; 2020; 11():702. PubMed ID: 32391013
[TBL] [Abstract][Full Text] [Related]
37. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
Lee YH; Kim CH
Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
[TBL] [Abstract][Full Text] [Related]
38. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T cell therapies for multiple myeloma.
Wu C; Zhang L; Brockman QR; Zhan F; Chen L
J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
[TBL] [Abstract][Full Text] [Related]
40. Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity.
Shi X; Zhang D; Li F; Zhang Z; Wang S; Xuan Y; Ping Y; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):127. PubMed ID: 31783892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
